SCHEMBL4784976

SCHEMBL4784976

CCCCCNCC(=O)CNCCCCC

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.57
TSHR P16473 1/20 0.57
EPHX1 P07099 8/20 0.50
GAA P10253 1/20 0.47
S1PR2 O95136 5/20 0.47
S1PR4 O95977 5/20 0.47
S1PR1 P21453 5/20 0.47
S1PR3 Q99500 5/20 0.47
S1PR5 Q9H228 1/20 0.47
ADH1B P00325 2/20 0.46
ADH1C P00326 2/20 0.46
ADH1A P07327 2/20 0.46
ADH7 P40394 2/20 0.46
ADH4 P08319 1/20 0.46
PAOX Q6QHF9 1/20 0.45
CASP2 P42575 1/20 0.45
ZDHHC20 Q5W0Z9 1/20 0.42
ZDHHC2 Q9UIJ5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9814881 0.92 GAA (0.53) ALDH1A1TSHREPHX1GAAS1PR2
SCHEMBL14422371 0.88 MAOA (0.46) ALDH1A1TSHREPHX1S1PR2S1PR4
SCHEMBL22591965 0.87 KMT2A (0.52) ALDH1A1TSHREPHX1CASP2
SCHEMBL9827229 0.87 ALDH1A1 (0.48) ALDH1A1TSHREPHX1GAAS1PR2
SCHEMBL28576364 0.85 EPHX1 (0.47) ALDH1A1TSHREPHX1S1PR2S1PR4
SCHEMBL278308 0.83 AKR1B1 (0.50) ALDH1A1TSHR
SCHEMBL6212305 0.83 ALDH1A1 (0.55) ALDH1A1TSHREPHX1GAAS1PR2
SCHEMBL11500948 0.83 ALDH1A1 (0.55) ALDH1A1TSHREPHX1GAAS1PR2
SCHEMBL22336404 0.83 GAA (0.50) ALDH1A1TSHREPHX1GAAS1PR2
SCHEMBL10423198 0.83 ALDH1A1 (0.55) ALDH1A1TSHREPHX1GAAS1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060020001-A1 Use of cathepsin k inhibitors for the treatment of glaucoma ALCON, INC. (CH) 2006-01-26 US claimed
WO-2004058238-A1 USE OF CATHEPSIN K INHIBITORS FOR THE TREATMENT OF GLAUCOMA ALCON, INC. (CH) 2004-07-15 WO claimed
US-20240190837-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYCHRONICITY PHARMA INC (US) 2024-06-13 US disclosed
US-20220411399-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYCHRONICITY PHARMA INC (US) 2022-12-29 US disclosed
EP-3939971-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. (US) 2022-01-19 EP disclosed
US-20210171495-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2021-06-10 US disclosed
EP-3129366-B1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS SYNCHRONICITY PHARMA INC (US) 2021-06-09 EP disclosed
US-10759777-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators Synchronicity Pharma, Inc. (US) 2020-09-01 US disclosed
US-10383880-B2 Carbazole-containing sulfonamides as cryptochrome modulators Synchronicity (US) 2019-08-20 US disclosed
US-20190241540-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2019-08-08 US disclosed
US-20180334446-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2018-11-22 US disclosed
EP-1532134-B1 NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AVENTIS PHARMA SA (FR) 2008-06-04 EP disclosed
US-20060020001-A1 Use of cathepsin k inhibitors for the treatment of glaucoma ALCON, INC. (CH) 2006-01-26 US disclosed
US-20050154048-A1 Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use AVENTIS PHARMA S.A. (FR) 2005-07-14 US disclosed
US-20040247527-A1 Multifunctional photodynamic agents for treating of disease MPA TECHNOLOGIES, INC. 2004-12-09 US disclosed
US-20040146463-A1 Functional MRI agents for cancer imaging NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-07-29 US disclosed
EP-1246824-B1 CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AVENTIS PHARMA SA (FR) 2004-06-09 EP disclosed
US-6673333-B1 COMPRISING A FIRST GD(III) ION BOUND TO A FIRST CHELATOR; GD(III) ION HAS COORDINATION ATOMS IN AT LEAST 7 COORDINATION SITES; BOUND TO TUMOR ASSOCIATED ACTIVATIVLE GUARDING MOIETY RESEARCH CORPORATION TECHNOLOGIES, INC. 2004-01-06 US disclosed
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof AVENTIS PHARMA S.A. (FR) 2003-05-29 US disclosed
US-20030021750-A1 Novel functional agents for magnetic resonance imaging METAPROBE, INC. 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241540-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS ALDH1A1 2882/4885TSHR 660/4885EPHX1 3583/4885
US-20180334446-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS ALDH1A1 2882/4885TSHR 660/4885EPHX1 3583/4885
US-20050154048-A1 Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use CTSZ, CTSE, CTSS ALDH1A1 959/4885TSHR 2023/4885EPHX1 878/4885
US-20210171495-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS ALDH1A1 2882/4885TSHR 660/4885EPHX1 3583/4885
US-10759777-B2 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators CRY1, CRY2, HCCS ALDH1A1 2882/4885TSHR 660/4885EPHX1 3583/4885
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof HRH4, HRH3, HRH2 ALDH1A1 3225/4885TSHR 328/4885EPHX1 2039/4885
US-20220411399-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS ALDH1A1 2882/4885TSHR 660/4885EPHX1 3583/4885
US-20030021750-A1 Novel functional agents for magnetic resonance imaging FABP7, RXFP1, MRGPRX2 ALDH1A1 3937/4885TSHR 1290/4885EPHX1 1809/4885
US-10383880-B2 Carbazole-containing sulfonamides as cryptochrome modulators CRY1, CRY2, CRYAB ALDH1A1 1829/4885TSHR 477/4885EPHX1 1879/4885
US-20240190837-A1 CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS CRY1, CRY2, HCCS ALDH1A1 2882/4885TSHR 660/4885EPHX1 3583/4885
US-20040146463-A1 Functional MRI agents for cancer imaging TSG101, SMARCE1, SMARCA1 ALDH1A1 4125/4885TSHR 3065/4885EPHX1 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.